- Home
- VYNE vs ECOR Comparison
VYNE vs ECOR Comparison
Compare VYNE & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- ECOR
- Stock Information
- Founded
- VYNE 2003
- ECOR 2005
- Country
- VYNE United States
- ECOR United States
- Employees
- VYNE N/A
- ECOR N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VYNE Health Care
- ECOR Health Care
- Exchange
- VYNE Nasdaq
- ECOR Nasdaq
- Market Cap
- VYNE 35.7M
- ECOR 40.1M
- IPO Year
- VYNE 2018
- ECOR 2018
- Fundamental
- Price
- VYNE $1.33
- ECOR $4.98
- Analyst Decision
- VYNE Strong Buy
- ECOR Strong Buy
- Analyst Count
- VYNE 2
- ECOR 2
- Target Price
- VYNE $6.25
- ECOR $25.50
- AVG Volume (30 Days)
- VYNE 223.6K
- ECOR 122.7K
- Earning Date
- VYNE 05-08-2025
- ECOR 05-07-2025
- Dividend Yield
- VYNE N/A
- ECOR N/A
- EPS Growth
- VYNE N/A
- ECOR N/A
- EPS
- VYNE N/A
- ECOR N/A
- Revenue
- VYNE $605,000.00
- ECOR $25,182,000.00
- Revenue This Year
- VYNE N/A
- ECOR $32.20
- Revenue Next Year
- VYNE N/A
- ECOR $46.27
- P/E Ratio
- VYNE N/A
- ECOR N/A
- Revenue Growth
- VYNE 18.16
- ECOR 57.09
- 52 Week Low
- VYNE $1.27
- ECOR $5.02
- 52 Week High
- VYNE $4.30
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- VYNE 33.79
- ECOR 30.12
- Support Level
- VYNE $1.27
- ECOR $6.01
- Resistance Level
- VYNE $1.41
- ECOR $7.14
- Average True Range (ATR)
- VYNE 0.11
- ECOR 0.75
- MACD
- VYNE -0.02
- ECOR -0.03
- Stochastic Oscillator
- VYNE 0.00
- ECOR 4.80
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.